Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)
Open Access
- 1 July 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 5 (7), 819-824
- https://doi.org/10.1001/jamacardio.2020.1096
Abstract
The first cases of coronavirus disease 2019 (COVID-19) were reported in December 2019, originating in Wuhan, China,1 with rapid spread worldwide, and COVID-19 became a public health emergency of international concern.2 The pathogen has been identified as a novel enveloped RNA beta-coronavirus and has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).3 The clinical course of SARS-CoV-2 infection is mostly characterized by respiratory tract symptoms, including fever, cough, pharyngodynia, fatigue, and complications related to pneumonia and acute respiratory distress syndrome.4Keywords
This publication has 13 references indexed in Scilit:
- Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studiesBioScience Trends, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- MyocarditisCirculation Research, 2016
- Cardiovascular Magnetic Resonance in Myocarditis: A JACC White PaperJournal of the American College of Cardiology, 2009
- Molecular Biology and Pathogenesis of Viral MyocarditisAnnual review of pathology, 2008
- Cardiovascular complications of severe acute respiratory syndromePublished by Oxford University Press (OUP) ,2006
- Noninvasive diagnosis of biopsy-proven cardiac amyloidosisJournal of the American College of Cardiology, 2004
- Advances in the Understanding of MyocarditisCirculation, 2001